Based on the prevalence of FGFR alterations in breast cancer and their relevance during resistance to CDK4/6 inhibition, as discussed above, targeting aberrant FGFR activity may hold clinical value for treating therapy-resistant BC. This evidence concerns the gene CDK4 and breast cancer.